ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026
Comparative analysis of different modalities of radiotherapy in vestibular schwannoma: tumor control, symptom evolution, and toxicity profiles.
Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStereotactic radiotherapy (SRT) is a standard treatment for vestibular schwannoma (VS). Long-term comparative data on single-fraction radiosurgery (SRS) versus normofractionated SRT (NFSRT) are limited.
methodsWe retrospectively analyzed 175 VS patients treated between 1998 and 2023 (SRS n = 69; NFSRT n = 106; median age 61 years; median follow-up 46 months). Tumor control was evaluated with Kaplan-Meier and Cox regression. Group differences were tested with Mann-Whitney U and chi-square/Fisher's exact tests. Symptom changes were assessed with McNemar tests, and binary logistic regression identified predictors of acute and late toxicity.
resultsOverall, in-field PFS was 94.3% and out-field was PFS was 99.4%. All 10 recurrences (median 58.5 months) occurred in NFSRT patients treated with 55.8-56 Gy. Higher total dose predicted recurrence (HR = 2.97; p = 0.003). At baseline, 97.1% reported symptoms (hearing loss 86.9%, vertigo 48.0%, tinnitus 42.3%). After therapy, symptoms remained stable, except the incidence of headache, which increased from 14.3% to 22.3% (p = 0.02). Early toxicities were more common after NFSRT, including headache (OR = 4.05; p = 0.01), fatigue (OR = 5.12; p = 0.01), and alopecia (OR = 19.9; p = 0.04), but had resolved by late follow-up. Age and prior surgery predicted vertigo patterns over time. Radionecrosis was rare (0.6%).
conclusionBoth SRS and NFSRT achieve excellent long-term tumor control with low severe toxicity. For NFSRT, normofractionated doses above 55 Gy did not improve efficacy and may increase the recurrence risk, supporting moderate-dose regimens (50-54 Gy). Symptom stabilization confirms the safety of SRT, though headache and vertigo remain relevant long-term issues. Careful dose selection, patient counseling, and rehabilitation are essential to optimize outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.